Statin exposure associated with lower all-cause, pulmonary mortality
FRIDAY, Sept. 8, 2017 (HealthDay News) — Statin use is associated with a reduced risk of all-cause and pulmonary-related mortality in patients with chronic obstructive pulmonary disease (COPD), according to a study published online Sept. 7 in Chest.
Adam Raymakers, from the University of British Columbia in Canada, and colleagues evaluated the association of statin use with all-cause and pulmonary-related mortality in patients with COPD. They used individual prescription records to identify 39,678 COPD patients, of whom 7,775 had received at least one statin in the one-year period after COPD diagnosis.
The researchers found that there were 1,446 all-cause deaths recorded within the cohort in the one-year exposure window. In multivariate analysis, the estimated hazard ratio for statin exposure was 0.79, suggesting a 21 percent reduction in the risk of all-cause mortality. There was also a considerable reduction in the risk for pulmonary-related mortality (HR, 0.55).
“This study shows that statin use in a population-based cohort of COPD patients may confer benefits in terms of reduced pulmonary-related and all-cause mortality,” conclude the authors.
One author reports financial ties to the pharmaceutical industry.
Copyright © 2017 HealthDay. All rights reserved.
